Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
5-HT Receptors
8%
5-HT System
8%
5-HT2C Receptor
8%
5-HT2C Receptor Agonist
25%
5-hydroxytryptamine
16%
Addictive Behavior
8%
Addictive Drugs
8%
Advance Therapy
25%
Alcohol
25%
Alcohol Administration
16%
Alcohol Intake
16%
Alcohol Reduction
16%
Alcohol Reward
16%
Alcohol Use Motives
33%
Alcohol-related
33%
Balanced Design
16%
Behavioral Indices
8%
Cigarette Smokers
25%
Cigarette Smoking
25%
Cost-effective Alternatives
25%
Critical Groups
25%
Development Strategy
25%
Dopamine Function
8%
Glucagon
16%
Glucagon-like peptide-1 Receptor (GLP-1R)
16%
Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs)
33%
Health Burden
25%
Health Risk
25%
Human Data
25%
Human Laboratory
100%
Human Participants
16%
Human Trials
8%
Impulsivity
16%
Incretin Hormones
16%
Laboratory Screening
100%
Long-term Health
25%
Lorcaserin
50%
Medication Development
25%
Monotherapy
16%
Motivation
16%
NIAAA
25%
Nicotine
25%
Nicotine Reduction
16%
Pharmacological Development
25%
Phase I Trial
8%
Placebo
8%
Public Health Impact
16%
Randomized Controlled Trial
25%
Repurposing
8%
Route of Administration
16%
Screening Procedure
16%
Screening Trials
8%
Semaglutide
50%
Serotonin
8%
Smokers
66%
Smoking Cessation
8%
Societal Burden
25%
Targeted Treatment
25%
Treatment Mechanisms
8%
Use Report
16%
Weight Management
8%
Within-subject
25%
Medicine and Dentistry
Addictive Behavior
6%
Alcoholic Polyneuropathy
100%
Cigarette Smoking
25%
Clinical Trial
6%
Dopamine
6%
Drug Therapy
12%
Glucagon
6%
Glucagon Like Peptide 1 Receptor
6%
Glucagon-Like Peptide-1 Agonist
12%
Health Care Cost
12%
Impulsiveness
12%
Incretin
6%
Monotherapy
6%
Nicotine
18%
Nicotine Withdrawal
6%
Peptide
6%
Placebo
6%
Public Health
6%
Randomized Controlled Trial
12%
Receptor
25%
Semaglutide
50%
Serotonin
31%
Targeted Therapy
12%
Weight Management
6%
Neuroscience
5-HT2C Receptor
6%
5-HT2C Receptor Agonists
18%
Addiction
6%
Alcoholism
50%
Crossover Study
6%
Dopamine
6%
Drug Therapy
6%
Impulsivity
12%
Lorcaserin
50%
Nicotine
6%
Placebo
6%
Randomized Controlled Trial
6%
Serotonin
31%